2024 World Conference on Lung Cancer (WCLC) - Posters-P4.14C.02 Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma : A Single Center Retrospective Study

P4.14C.02 Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma : A Single Center Retrospective Study

Back to course

Pdf Summary

This retrospective study conducted at Hyogo Medical University analyzes the effectiveness and safety of Nivolumab, an immune checkpoint inhibitor, in treating patients with relapsed pleural mesothelioma. Historically, mesothelioma treatment options have been limited, and Nivolumab’s approval by Japanese regulatory authorities marked a significant advancement, addressing a critical therapeutic gap. <br /><br />The study focused on 83 patients treated with Nivolumab between August 2018 and May 2022. Patient demographics included a median age of 73 with a majority being male (77.11%). The effectiveness was evaluated using modified RECIST criteria, and safety was assessed by CTCAE version 5.0 regarding treatment-related adverse events (TRAEs). <br /><br />Outcomes demonstrated that the administration of Nivolumab improved progression-free survival (PFS) and overall survival (OS) compared to previous studies, indicating its beneficial role even in later-line treatments, especially for patients with good performance status (PS). The overall response rate (ORR) was 19.3%, and the disease control rate (DCR) was at 55.42%. Multivariate analysis revealed that better outcomes were associated with factors such as lower PS scores and treatment with fewer previous lines of therapy. <br /><br />Safety profiles were considered acceptable, with 54.22% of patients experiencing some form of TRAE, but only 7.23% experiencing grade 3 adverse events. Hypothyroidism and rash were common, although severe instances, like interstitial lung disease, were noted but rare. <br /><br />Overall, the study concludes that Nivolumab is a viable option for managing relapsed pleural mesothelioma in real-world settings, offering an increase in PFS and OS with a manageable safety profile. These findings advocate for the active consideration of Nivolumab in treatment regimes, particularly for patients displaying good performance statuses.

Asset Subtitle

Tomoki Higashiyama

Meta Tag

Speaker Tomoki Higashiyama

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

Nivolumab

pleural mesothelioma

immune checkpoint inhibitor

Hyogo Medical University

progression-free survival

overall survival

treatment-related adverse events

modified RECIST criteria

Japanese regulatory approval

real-world settings